Ashita Waterston Beatson West of Scotland Cancer Centre
|
|
- Ethelbert Owens
- 6 years ago
- Views:
Transcription
1 Ashita Waterston Beatson West of Scotland Cancer Centre
2 Aim of treatment Scheduling and choice of treatments are dictated by aim: Down staging for resectability: upfront intensive Prolong survival: combination upfront Quality of life slower pace of progression: sequential and intermittent
3 Factors to consider when choosing treatments Age/ comorbidity Service delivery Any prior treatment Government Rate of progression Oligometastases
4 Primary CRC tumor localization (left vs right) is a potential biomarker Right colon (ascending) Transverse colon Small intestine Left colon (descending) Rectum Anus Sigmoid (colon) Right-sided tumors ~40% (increasing)* Associated with: Older, female patients Mucinous, signet-ring histology Microsatellite instability Poorly differentiated KRAS and BRAF mutations EGFR expression *High-incidence CRC populations Left-sided tumors ~60%* Associated with: Chromosomal instability p53 mutation COX2 expression Aneuploidy High EGFR ligand expression (COIN study) Iacopetti, B. Int J Cancer 2002;101: ; Brule SY, et al. ASCO 2013 (Abstract No. 3528); Adams R, et al. ASCO 2012 (Abstract No. 3516)
5 Chemotherapy back bone
6 Treatment arms: GERCOR Study R A N D O M I S A T I O N Arm A FOLFIRI irinotecan 180 mg/m 2 IV + simplified LV5FU Arm B FOLFOX6 L-OHP 100 mg/m 2 IV + simplified LV5FU until progression until progression FOLFOX6 FOLFIRI until progression until progression Tournigand et al. J Clin Oncol. 2004;22:
7 Efficacy: GERCOR Study Arm A FOLFIRI FOLFOX Arm B FOLFOX FOLFIRI N Confirmed RR 56% 15% 54% 4% PFS (Months) Survival (Months) No statistically significant differences in 1 st or 2 nd line therapy RR or PFS and OS The study was designed for the two-sided log-rank test to have 80% power to detect a 20% difference in the proportion of patients without progression at 15 months (60% in arm A, 40% in arm B; type I error of 5%, type II error of 20%) Tournigand et al. J Clin Oncol. 2004;22:
8 XELOX as first-line therapy in CRC: Protocol NO16966 Large international phase III trial (n=700): first-line therapy for mcrc 3 weekly cycle Capecitabine 1000mg/m 2 bd D week rest Oxaliplatin 130mg/m 2 R D1 bolus 5fu D1 bolus 5fu 2 weekly cycle LV INF 5FU LV INF 5FU Oxaliplatin 85mg/m 2 Cassidy et al, JCO 2008
9 Toxicity % Toxicity XELOX FOLFOX Grade 3/4 neutropaenia 7 44 Febrile neutropaenia Grade 3 diarrhoea Grade 3 HFS 6 1
10 Efficacy Protocol RR (%) XELOX 47 PFS (months) 7.3 HR=1.02 OS (months) 19 HR=0.99 FOLFOX* *Cassidy ASCO GI symposium 2008/9
11 Slower growing tumours Safety Patience preference FOCUS: sequential 5FU FOLFOX/FOLFIRI versus upfront combination. No difference Maughan Lancet 2007 CAIRO: sequential capecitabine-irinotecan-xelox versus combination Xeliri Xelox. No difference OS Koopman Lancet 2007
12 Targeted therapy in CRC The EGFR signaling pathway plays an essential role in colorectal carcinogenesis and progression. This makes it an attractive therapeutic target. The MAPK and PI3K pathways. Growth factor binding to receptor tyrosine kinase results in activation of the MAPK signaling pathway (RAS-RAF-MEK-ERK) and the PI3K pathway (PI3K-AKT-mTOR) (
13 Proportion alive, % Overall survival (proportion) Overall survival (proportion) CRYSTAL n Months (95% CI) FOLFIRI ( ) Cet + FOLFIRI ( ) HR (95% CI ) p= OPUS n Months (95% CI) FOLFOX ( ) Cet + FOLFOX ( ) HR (95% CI ) p= Months Months PRIME n Months (95% CI) FOLFOX ( ) Pani + FOLFOX Months ( ) HR 0.83 (95% CI ) p=0.027 Van Cutsem E, et al. J Clin Oncol 2011;29: ; Bokemeyer C, et al. Ann Oncol 2011;22: ; Douillard J-Y, et al. ASCO 2013 (Abstract No. 3620)
14 Proportion alive, % Overall survival (proportion) Overall survival (proportion) Effect of EGFR inhibitor treatment in KRAS 12/13 mutant population: OS CRYSTAL n Months (95% CI) FOLFIRI ( ) Cet + FOLFIRI ( ) HR (95% CI ) p=0.75 OPUS n Months (95% CI) FOLFOX ( ) Cet + FOLFOX ( ) HR 1.29 (95% CI ) p= Months Months PRIME n Months (95% CI) FOLFOX ( ) Pani + FOLFOX ( ) HR 1.16 (95% CI ) p= Months Van Cutsem E, et al. J Clin Oncol 2011;29: ; Bokemeyer C, et al. Ann Oncol 2011;22: ; Douillard J-Y, et al. ASCO 2013 (Abstract No. 3620)
15 Tested mutations K R A S e x o n 2 w i l d - t y p e s u b s e t K R A S E X O N 1 E X O N 2 E X O N 3 E X O N w t % 4. 9 % N R A S E X O N 1 E X O N 2 E X O N 3 E X O N % 2 % 0 % B R A F E X O N 1 1 E X O N % 1 0 % FIRE-3 presentation ECC September 2013
16 Distribution of mutations in mcrc FIRE-3 presentation ECC September 2013
17 FIRE-3 study design FIRE-3 presentation ECC September 2013
18 Overall survival: RAS* wild-type Median Duration of Treatment 5 mo (all 3 agents) Median PFS 10 mo FIRE-3 presentation ECC September 2013
19 Second-line treatment: RAS evaluable population (N=407) 2nd-line treatment: RAS evaluable population (N=407) Alive after 1st-line therapy Any 2nd-line therapy FOLFIRI + Cetuximab N= % (174/205) 78.7% (137/174) FOLFIRI + Bevacizumab N= % (169/202) 76.9% (130/169) 2nd-line substances, % n=137 (100) n=130 (100) Fluoropyrimidine % Oxaliplatin % Irinotecan % Bevacizumab % Anti-EGFR mab % FIRE-3 presentation ECC September FIRE-3 Presentation ECC September 2013 Treatment with a substance not 2013 being part of 1st-line therapy
20 mcrc 1st-line KRAS wild type (codons 12,13) N = 1140 FOLFIRI or FOLFOX Chemo + Cetuximab Chemo + Bevacizumab 1 Endpoint: Overall Survival A Venook et al. ASCO 2014
21 CALGB/SWOG 80405: Eligibility Criteria Untreated Metastatic CRC Tumor KRAS wild type codons 12 & 13 > 12 months since adjuvant therapy ECOG 0-1 Preserved organ function AT ENROLLMENT CHOOSE: FOLFOX or FOLFIRI INTENT: Palliative or Part of strategy to resect all metastases
22 CALGB/SWOG 80405: Overall Survival Arm N (Events) OS (m) Median 95% CI Chemo + Cetux 578 (375) Chemo + Bev 559 (371) P=0.34 HR ( )
23 National Clinical Trials Network NCI CANADA 3,100 Institutions 14,000 Investigators
24 CALGB / SWOG 80405: WHY DID IT TAKE TEN YEARS? Original Design Unselected CHEMO + BEV v. CHEMO + CETUX v. CHEMO + BEV / CETUX AMEN D CLOSE Final Design KRAS wt CHEMO + BEV v. CHEMO + CETUX /2014 DATA RELEASE [-----OPEN ] [------OPEN----- ] Presented by:
25 First-line treatment RAS wild-type PRIME Study Metastatic CRC RAS wild-type N=512 FOLFOX + Panitumumab PFS (months) OS (months) FOLFOX p=0.004 p=0.04 Duillard NEJM Sept 2013
26 First-line treatment RAS wild-type mcrc Approximately 50% population within FIRE-3 Study? Scottish population Therefore patients with RAS wild-type where the intention is to increase survival: FOLFIRI and cetuximab Panitimumab and FOLFOX less evidence for the combination and has not gone through SMC Duration of treatment 6 months or until progression
27 Treatment in patients with RAS mutation The role of anti VEGF treatment and with what chemotherapy back bone Current Practice: Bevacizumab +FOLFIRI +FOLFOX The Evidence:
28 Phase III trial of IFL ± bevacizumab: Study design Bolus IFL + placebo (n=411) No bevacizumab past disease progression Previously untreated metastatic CRC Bolus IFL + bevacizumab (n=402) May receive bevacizumab past disease progression IFL: 5-FU/LV + bevacizumab (n=110) May receive bevacizumab past disease progression bolus 5-FU 500mg/m 2 leucovorin 20mg/m 2 irinotecan 125mg/m 2 given 4/6 weeks 5-FU/LV: bolus 5-FU 500mg/m 2 leucovorin 500mg/m 2 given 6/8 weeks Bevacizumab: 5mg/kg every 2 weeks Hurwitz H, et al. NEJM June 2004
29 Phase III trial of IFL ± bevacizumab: Probability of survival Effect of bevacizumab on overall survival Kaplan-Meier curve ARM n OS (mo) IFL IFL-Bev Hazard ratio = 0.66, p= IFL + placebo IFL + bevacizumab Survival (months) Hurwitz H, et al. NEJM June 2004
30 NO16966 study design
31 General progression free survival: chemotherapy ± bevacizumab
32 Open access studies Brite - USA bevacizumab + chemo Beat - European bevacizumab + chemo, n= % FOLFOX, 26% FOLFIRI, 18% Xelox, 16% monotherapy Toxicity 3% bleeding, 2% GI perf, 1% arterial thromboembolic disease, 5.3% hypertension, 1% proteinuria PFS: 10 months, OS: 22.7 months Van Cutsem Annals oncology 2009
33 Treatment RAS mutation In Scotland Is this dependent on second-line option Data for bevacizumab and FOLFOX E3200 study Data for aflibercept and FOLFIRI Velour study
34
35 Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial Josep Tabernero, Eric Van Cutsem, Radek Lakomý, Jana Prausová, Paul Ruff, Guy A. van Hazel, Vladimir M. Moiseyenko, David R. Ferry, Joseph J. McKendrick, Karen Soussan-Lazard, Soazig Chevalier, Carmen J. Allegra. European Journal of Cancer , DOI: ( /j.ejca )
36 Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 Kaplan-Meier estimates of survival by treatment. Folfox+bev Folfox Bev Bruce J. Giantonio et al. JCO 2007;25: by American Society of Clinical Oncology
37 Prognostic impact KRAS/NRAS and BRAF mutation Patients have reduced overall survival No evidence predictive of therapy Therefore should we treat patients more intensively first line
38 Prognostic impact of KRAS and BRAF mutations FOCUS trial Not predictive for oxaliplatin or irinotecan combination chemotherapy Richman S D et al. JCO 2009;27: by American Society of Clinical Oncology
39 OS estimate CRYSTAL/OPUS pooled analysis: BRAF mt prognostic, not predictive KRAS wt/braf wt HR (95% CI): 0.84 ( ); p=0.048 CT + cetuximab (n=349): mos 24.8 mo CT (n=381): mos 21.1 mo KRAS wt/braf mt HR (95% CI): 0.62 ( ); p=0.076 CT + cetuximab (n=32): mos 14.1 mo CT (n=38): mos 9.9 mo CRYSTAL/OPUS: Pooled analysis of OS in patients with KRAS wt/braf wt or mt tumors Time (months) Bokemeyer C, et al. Eur J Cancer 2012;48:
40 FOLFOXIRI and bevacizumab: TRIBE Folfoxiri + bevacizumab 12 cycles max 5 FU + bevacizumab Until progression PFS (months) OS (months) mcrc N=508 Folfoxiri 12 cycles max 5 FU + Until progression p= p=0.125 Cremilini et al Lance Oncology vol 16 oct 2015
41 First-line treatment RAS mutation Phase III trial of FOLFOXIRI and bevacizumab subgroup in 28 BRAF mutated patients Median PFS 7 months and OS 13.4 months Numbers small but no difference in treatment
42 oligometastases Downstaging for resection-maximise intensity: RAS wild-type: cetuximab and FOLFIRI Triple therapy RAS mutation Folfoxiri +? bevacizumab Olivia ASCO 2013 Liver limited metastatic CRC (n= 80) FOLFOXIRI + bevacizumab FOLFOX + bevacizumab R0/ p=ns Med PFS (months) p=0.009 Fanconi Asco 2013
43 PS 1/0 Progressed through all current lines of treatment Whats next
44 Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Med 0s 6.4 months Med os 5.0 months P=0.0052? Clinical significance Grothey et al vol 381 Lancet 2013
45 TAS 102 in refractory metastastic colon cancer Recourse study Med os 7.1 months Med os 5.3 months TAS 102 oral combined analogue of thymidine nucleic acid Trifluridine and a thymidine phospholrylate inhibitor tipiracil hydrochloride. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer Robert J. Mayer et al N Engl J Med 2015; 372: May 14, 2015
46 Expanded Access Programmes Drug Companies can promote expanded access programmes Allows access to Novel therapies by Clinicians Limited Time frame Companies can get real life data Time consuming Inclusion/Exclusion criteria vary
47 +ve Phase III RCT Expanded Access Programmes FDA/EMEA Approval Expanded Access Programmes SMC Approval Expanded Access Programmes
48 Applications to SMC Sent by Drug company Expert Advice Templates include Current practice Any guidelines on treatment Unmet Need Service implications
49 SMC Process On EMEA approval Drug Companies can apply to SMC New drugs committee Can ask for End of life drugs includes PACE process Also Orphan and extra Orphan status
50 PACE Process Panel made up of pharmacists, SMC personnel, Patient advocate-charity, Patients, Oncology expert. Template sent prior looking: Severity of condition, unmet need, effect on patient and family SMC New drugs committee reject Drug Pace Meeting
51 Approval Process SMC meet with PACE Information Final decision outcome published 4 weeks later During 4 weeks need Protocol to PASG Meet to approve and send to Drugs therapeutic committee Update Clinical management guideline
52 New kid on the block PD-1 Blockade in Tumors with Mismatch-Repair Deficiency Dung T. Le, et al N Engl J Med Volume 372(26): June 25, 2015
53 CTLA-4 and PD-1/L1 Checkpoint Blockade Priming phase (lymph node) Effector phase (peripheral tissue) Dendritic cell T cell T-cell migration T cell Cancer cell MH C TCR TCR MHC Dendritic cell B7 CD28 CTLA-4 T cell T cell PD-1 PD-L1 Cancer cell Ribas A. N Engl J Med. 2012;366:
54 Study design Phase 2 to evaluate immune checkpoint blockade in Pts tumours with or without DNA MMR deficiency Recruited patients with HNPCC One of the germline mismatch genes is defective plus a second somatic mutation & recruited pts with sporadic MMR-deficiency Both alleles inactive through somatic mutation 3 cohorts A- MMR-deficient colorectal adenocarcinomas B- MMR-proficient colorectal adenocarcinomas C- MMR-deficient cancers of types other than colorectal
55 Study design: Eligibility Inclusion Age >18 CRC >2 treatment Other cancers >1 treatment ECOG 0-1 Life expectancy >3 months Adequate liver, kidney and marrow function Exclusion >50% of liver involved Unstable CNS mets ( no steroids) Chemo in last 14 days Patients with a history of prior treatment with anti- PD-1, anti-pd-l1, anti- PDL2,anti-CD137, anti- OX-40, anti-cd40, or anti-ctla-4 antibodies. (chronic steriods were allowed)
56 Study design Pembrolizumab was administered iv at a dose of 10mg/kg every 14 days Safety assessments were performed before each treatment Tumour markers were measured at the start of each cycle Radiographic assessment was performed at 12 weeks and every 8 weeks thereafter Mismatch repair status was assessed by assessing the level of microsatellite instability Primary tumour samples and matched blood samples were collected to examine potential for mutant peptide binding A total estimate of the total number of mutation-associated neoantigens in each tumour was made
57 Clinical Responses to Pembrolizumab Treatment. Le DT et al. N Engl J Med 2015;372:
58 Clinical Benefit of Pembrolizumab according to MMR Status. Le DT et al. N Engl J Med 2015;372:
59 Results: tumour markers / genomic analysis Mutational burden 9 deficient tumours analysed Mean of 1782 somatic mutations per tumour 578 neoantigens 6 proficient tumours analysed Mean of 73 somatic mutations per tumour 21 neoantigens High number of somatic mutations was associated with longer PFS and a trend to OS CEA measured in cohorts A and B 29/32 above the upper limit of normal Cohort A 7/10 CEA fell Cohort B 0/19 CEA fell Cohort C 4 patients had measurable tumour marker 3/4 fell Degree of fall of CEA after 1 dose was predictive of PFS (p=0.01) and OS (p=0.02) Preceded radiographic response
60 Discussion & Conclusion Supports hypothesis MMR deficient tumours are more responsive to PD-1 treatment Supported by previous evidence of Th-1 infiltration in tumour microenvironment MMR deficient tumours previously shown to strongly express other checkpoint ligands Suggests the greater the neoantigens the greater the response MMR status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. Changes in CEA corresponded with clinical benefit Evaluation of tumour genomics can help guide immunotherapy Phase III trial awaited
61 Over all Conclusion Biomarker analysis of all Stage IV patients Analyse KRAS, NRAS and BRAF (MMR) Clarify aims of therapy Down staging for resection Reduced survival-intensive Prolong survival Minimal toxicities RAS wild-type: cetuximab and FOLFIRI RAS mutation: doublet and antiangiogenic (second line)
62
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationKonzepte bei der Therapie des metastasierten kolorektalen Karzinoms
21. Ärzte Fortbildungskurs in Klinischer Onkologie 24.-26. Februar 2011 Kantonspital St. Gallen / Schweiz Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms Claus-Henning Köhne Klinik
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationTreatment of Advanced Colorectal Cancer
Treatment of Advanced Colorectal Cancer Alexis D. Leal, M.D. Assistant Professor, GI Medical Oncology University of Colorado Cancer Center Disclosures None Objectives Review the basics of advanced colorectal
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationMedical Therapy of Colorectal Cancer in the Biomarker Era
Medical Therapy of Colorectal Cancer in the Biomarker Era Axel Grothey Professor of Oncology Mayo Clinic College of Medicine Rochester, Minnesota Disclosures Consulting activities (honoraria went to the
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationRAS and BRAF in metastatic colorectal cancer management
Review Article RAS and BRAF in metastatic colorectal cancer management Jun Gong 1, May Cho 1, Marwan Fakih 2 1 Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA; 2 Medical
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationReview of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux
Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero
More informationWhat to do after 1st-line failure in mcrc?
What to do after 1st-line failure in mcrc? Werner Scheithauer Univ.Klinik für Innere Med. I & CCC, Med.Uni.Wien-AKH mcrc front-line treatment strategy today Updated results of head-to-head trials in mcrc,
More informationTHE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER
THE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Dept of GI Medical Oncology November 5, 2010
More informationThe role of Maintenance treatment Appropriate endpoints according to ESMO consensus
ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationFighting a Smarter War On Colon Cancer:
Fighting a Smarter War On Colon Cancer: Value as a new endpoint? John L. Marshall, MD Tel: (202) 444-0275 Fax: (202) 444-1229 http://lombardi.georgetown.edu/gi Stakeholder Motivation Stakeholders FDA CMS/Payers
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationWhat s New? Dr. Barbara Melosky
Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationNovel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer. Objectives
Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer Michael S. Lee, MD Assistant Professor of Medicine University of North Carolina Objectives Discuss important clinicopathologic
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More informationThe ESMO consensus conference on metastatic colorectal cancer
ESMO Preceptorship Programme Colorectal cancer Prague July, 6-7 2016 The ESMO consensus conference on metastatic colorectal cancer Andres Cervantes ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationWhat to do after 1 st line failure?
ESMO Preceptorship Programme Colorectal Cancer Singapore 20-22 nd 2016 JY Douillard MD PhD ESMO CMO What to do after 1 st line failure? mcrc: How to maximize survival? Improving 1st line therapy efficacy
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationBevacizumab is currently licensed for the following indication relevant for this NICE review:
Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationMetastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage. Dr Lee-Ann Jones
Metastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage Dr Lee-Ann Jones Aim Metastatic Colorectal Cancer: Past: 5FU, oxaliplatin, irinotecan..blanket treatment
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationMANAGEMENT OF ADVANCED COLORECTAL CANCER
MANAGEMENT OF ADVANCED COLORECTAL CANCER Alberto Sobrero IRCCS San Martino IST Genoa Italy Disclosures : Pfizer, Roche, Merck, Amgen, Celgene, Bayer, Sanofi, Nordic, Takeda,BMS, Syrtex, Servier outline
More informationDOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT?
DOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT? By: Dr. Dominik Modest, Medical Department III, Hospital of the University of Munich, Germany Dr. Andrea Sartore-Bianchi, Niguarda Cancer Center,
More informationColorectal Cancer Update Dr. Barb Melosky
Colorectal Cancer Update 2017 Dr. Barb Melosky bmelosky@bccancer.bc.ca Disclosure Research Support/P.I. Honoraria/Advisory Board Bayer Roche, Amgen, Bayer, Lilly Objectives 1) Demonstrate knowledge of
More informationDaniele Santini University Campus Bio-Medico Rome, Italy
Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationLa strategia terapeutica del carcinoma del colon metastatico
Dalla Capecitabina al TAS-102 Milano, 29 settembre 2016 La strategia terapeutica del carcinoma del colon metastatico Gianluca Masi U.O. di Oncologia Medica Universitaria Azienda Ospedaliero-Universitaria
More informationRight Drug for the Right Colorectal Patient: Select the Best Initial Therapy and What Comes After 5-FU/OXALI/IRINO?
Right Drug for the Right Colorectal Patient: Select the Best Initial Therapy and What Comes After 5-FU/OXALI/IRINO? Axel Grothey Professor of Oncology Minnesota -> Tennessee The Luxury of So Many Options...
More informationNuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos?
Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Prof. Dr. Paulo M. Hoff Instituto do Câncer do Estado de São Paulo - ICESP Faculdade de Medicina Universidade de São Paulo (USP) Conflicts
More informationKolorektalni karcinom- novosti u liječenju. PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić
Kolorektalni karcinom- novosti u liječenju PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić Kolorektalni karcinomnovosti u liječenju PANEL : Maja Banjin, Janja Ocvirk, Borislav
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More information2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer?
Medical Management of Colon and Rectal Cancer: An Overview Jonathan Grim, MD, PhD VA Puget Sound Health Care System Fred Hutchinson Cancer Research Center UW Medicine Outline / Learning Objectives Epidemiology
More informationUnderstanding predictive and prognostic markers
Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE Understanding predictive and prognostic markers Aimery de Gramont Prognostic
More informationManagement Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study
Management Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study Henaine AM; Chahine G; Massoud M; Salameh P; Awada S; Lahoud N; El
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationNew Options in Metastatic Colorectal Cancer. Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka
New Options in Metastatic Colorectal Cancer Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka 4 th most frequently diagnosed CA in the US 2 nd leading cause of CA death in the US Incidence
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationRelated Policies None
Medical Policy MP 2.04.53 BCBSA Ref. Policy: 2.04.53 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationRECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER
RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Rectal Cancer Pathway V8, April 2015 Diagnostic Workup: Bethesda Criteria: Pathology Review All patients H&P All patients Biopsy All patients Colonoscopy All patients CEA All Patients Chest/Abdominal/Pelvic
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationTargeted therapies in colorectal cancer: the dos, don ts, and future directions
Editorial Targeted therapies in colorectal cancer: the dos, don ts, and future directions Marwan Fakih City of Hope Comprehensive Cancer Center, 1500 E Duarte St, Duarte, CA 91010, USA Corresponding to:
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate
More informationMEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015
Supported by an Independent Educa1onal Grant from MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015 BY DR. GUILLEM ARGILES, BARCELONA, SPAIN Cancers of the Lower GI Tract RAISE: A RANDOMIZED, DOUBLE-BLIND,
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: KRAS, NRAS, and BRAF Variant Analysis
More informationTHE BEST OF ESMO 2016
THE BEST OF ESMO 2016 Colorectal cancer Pr Julien TAIEB, Sorbonne Paris Cité and Paris Descartes University Georges Pompidou European Hospital Paris, FRANCE esmo.org DISCLOSURES JT has received research
More informationUniversità degli Studi di Pisa Facoltà di Medicina e Chirurgia Scuola di Specializzazione in Oncologia
Università degli Studi di Pisa Facoltà di Medicina e Chirurgia Scuola di Specializzazione in Oncologia Tesi di Specializzazione EZH2 polymorphisms and outcome of metastatic colorectal cancer patients Candidato:
More informationOptimizing Sequencing Beyond Disease Progression After Second-Line Therapy in Metastatic Colorectal Cancer
Optimizing Sequencing Beyond Disease Progression After Second-Line Therapy in Metastatic Colorectal Cancer Kabir Mody, MD, and Tanios Bekaii-Saab, MD Abstract Colorectal cancer (CRC) remains a significant
More informationCost-effectiveness of Cetuximab and Panitumumab in First-line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer in Ontario
Cost-effectiveness of Cetuximab and Panitumumab in First-line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer in Ontario Emmanuel Ewara, Dr. Greg Zaric, Dr. Stephen Welch, Dr. Sisira
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationTobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1
Botrel et al. BMC Cancer (2016) 16:677 DOI 10.1186/s12885-016-2734-y RESEARCH ARTICLE Open Access Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated
More informationReview Article Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
BioMed Research International Volume 2016, Article ID 7590245, 14 pages http://dx.doi.org/10.1155/2016/7590245 Review Article Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More information